Introduction {#s1}
============

Mutations in *amyloid-beta precursor protein* (*APP*), *presenilin 1* and 2 (*PSEN1, PSEN2*) are known to cause early onset (\<60 years) familial Alzheimer disease (AD) [@pone.0031039-Cruts1]--[@pone.0031039-Goate1]. While initially considered to solely cause early onset AD (EOAD), mutations in *PSEN1* and *PSEN2* have been reported in several families with both late and early onset disease [@pone.0031039-Kauwe1]--[@pone.0031039-Tomaino1]. Screening for mutations in *PSEN1* has been performed mainly in early-onset families, although a small number of families including late onset (\>60 years) cases (\<100 families) were also screened [@pone.0031039-Rogaeva1], [@pone.0031039-Kauwe1]--[@pone.0031039-Larner1], [@pone.0031039-Arango1]--[@pone.0031039-deSilva1]. Similarly, mutation screening efforts in *APP*, which have historically been limited to exons 16 and 17, have focused on early onset families but have included some late onset families [@pone.0031039-Arango1], [@pone.0031039-Houlden1]--[@pone.0031039-Kamino1]. Screening of 40 late-onset AD (LOAD) families for *APP* mutations in the exons 16--17 identified a pathogenic *APP* mutation (Glu693Gly) with incomplete penetrance in a single family [@pone.0031039-Kamino1]. Mutations in *progranulin* (*GRN*) and in *microtubule associated protein tau* (*MAPT*) are an established cause of familial frontotemporal dementia (FTD) [@pone.0031039-VanDeerlin1], [@pone.0031039-Huey1]. Some individuals carrying these mutations have been reported with clinical manifestations indistinguishable from AD [@pone.0031039-Cortini1]--[@pone.0031039-Reed1], but the frequency of mutations in *GRN* and *MAPT* in clinical series of LOAD cases is unknown. The identification of mutations in these genes in cases with clinically diagnosed AD would change not only the diagnosis and treatment but create the need for genetic counseling.

While there has been considerable success in the identification of genes contributing to EOAD, LOAD is far more frequent, accounting for 99% of all AD cases. LOAD remains a less well understood disorder. The major genetic risk factor for LOAD is *APOE* genotype [@pone.0031039-The1]. The frequency of mutations in *APP*, *PSEN1*, *PSEN2* in LOAD families is unknown because no study has systematically screened these genes in a large series of LOAD families. Because LOAD is so much more common than EOAD, the presence of even a low frequency of mutations would represent a large number of affected families.

Alzheimer Disease is a complex disease and shows heritability of up to 80% [@pone.0031039-Gatz1]. Most recent genetic studies of AD have focused on the identification of common variants associated with risk for AD through genome-wide association studies (GWAS). These studies have identified several new genes that show significant association after multiple test correction in multiple datasets: *CLU*, *PICALM*, *BIN1*, *CR1*, *ABCA7*, *MS4A6A*, *CD33* and *CD2AP* [@pone.0031039-Harold1]--[@pone.0031039-Naj1]. However, each of these new signals only account for about 4--9% of the variance in AD susceptibility [@pone.0031039-ErtekinTaner1]. The total proportion of heritability explained by the genes that show an association with AD (including APOE) is estimated to be 23% [@pone.0031039-So1], therefore a large proportion of the heritability for LOAD remains unexplained.

GWAS studies are only able to identify common variants that are associated with disease. Importantly, the effect of rare variants cannot be determined in these studies. It has been suggested that the combined effect of rare deleterious mutations could explain a substantial fraction of genetic susceptibility to many common diseases [@pone.0031039-Nejentsev1]--[@pone.0031039-Kim1]. Rare alleles can only be identified through resequencing large populations.

In this study we have screened a large collection of LOAD families for mutations in *APP*, *PSEN1*, *PSEN2*, *MAPT and GRN*. We used a method that combines a pooled-DNA approach with next-generation sequencing technology and bioinformatics analyses [@pone.0031039-Druley1], [@pone.0031039-Vallania1] to identify rare and novel variants in these genes in 439 families with a history of LOAD and/or dementia in four or more family members ([Table 1](#pone-0031039-t001){ref-type="table"} and [2](#pone-0031039-t002){ref-type="table"}). This study allows us to accurately estimate the mutation frequency in these genes in LOAD and the effect of rare variants with risk for disease.

10.1371/journal.pone.0031039.t001

###### Distribution of the families by the number of affected individuals in each family.

![](pone.0031039.t001){#pone-0031039-t001-1}

  \# affected    \# families    \%     \# sequence variants    \%
  ------------- ------------- ------- ---------------------- -------
  28                  1        0.23             1             1.67
  20                  2        0.46             2             3.33
  19                  1        0.23             0             0.00
  17                  1        0.23             2             3.33
  16                  1        0.23             0             0.00
  15                  1        0.23             0             0.00
  14                  1        0.23             0             0.00
  13                  5        1.14             1             1.67
  12                  3        0.68             0             0.00
  11                  4        0.91             0             0.00
  10                 13        2.96             2             3.33
  9                  14        3.19             2             3.33
  8                  27        6.15             5             8.33
  7                  32        7.29             6             10.00
  6                  54        12.30            5             8.33
  5                  107       24.37            9             15.00
  4                  172       39.18            25            41.67
  TOTAL              439                        60           

The number of families with different numbers of affected individuals is shown. More than 50% of the families have 4 or 5 affected individuals. The number of sequence variants found in each group is also shown.

10.1371/journal.pone.0031039.t002

###### Demographic data for the cohort.
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  ------------- ------------------------------ --------------------------
  AAO (years)          Sequenced sample         69.92±8.37(range 30--92)
                 Families (mean age at onset)   72.80±5.62(range 60--89)
  Ethnicity           European ancestry                  76.5%
                       White- Hispanics                  14.6%
                       Black- Hispanics                   2.7%
                       African-American                   2.7%
                            others                        3.6%
  Diagnosis              Definite AD                     26.94%
                         Probable AD                     71.46%
                         Possible AD                     1.59%
  ------------- ------------------------------ --------------------------

The mean, the standard deviation and the range for the age at onset (AAO) for the sequenced samples and the families are shown. For the families the AAO represents the mean AAO of the affected individuals of each family.

Results {#s2}
=======

We identified 33 nonsense, missense and splice-site sequence variants in 60/439 (13.7%) individuals, including five known pathogenic variants in ten individuals (2.3%), and three novel potentially pathogenic alleles in four individuals (0.9%). An additional variant in *GRN*, reported previously to be non-pathogenic, because it was present in a very small number of unaffected samples, segregated perfectly with disease status, was not present in 2,692 control chromosomes and may be pathogenic. The fact that it was present in control individuals in previous studies may be because of incomplete penetrance. Pathogenic or likely-pathogenic variants were found in all genes except *PSEN2* ([Table 3](#pone-0031039-t003){ref-type="table"}). The frequency of rare variants in *APP*, *PSEN1* and *PSEN2* in this dataset was significantly higher than the frequency of rare variants found in these genes in three series not enriched for AD cases (GlaxoSmithKline study (GSK study), 1,000 genome project and Exome Variant Server). In the GlaxoSmithKline study (see [Materials and Methods](#s4){ref-type="sec"} and Supporting [Materials and Methods S1](#pone.0031039.s001){ref-type="supplementary-material"}; n = 12,481), a total of 376 novel and rare non-synonymous, variants were found in *APP*, *PSEN1* and *PSEN2* (2.91% of the samples), but we found 28 rare non-synonymous variants (6.38%) in our 439 samples (p = 6.82×10^−5^; OR = 2.19; 95%CI = 1.347--3.26). In the 1,000 genomes project only 25 rare (MAF\<0.05) non-synonymous, nonsense or splice-site variants were identified in these genes from three different populations (CEU, YRI and CHBJPT; (p = 5.09×10^−5^; OR = 2.21; 95%CI = 1.49--3.28; see Supporting [Materials and Methods S1](#pone.0031039.s001){ref-type="supplementary-material"}). The Exome Variant Server (<http://evs.gs.washington.edu/EVS/>) [@pone.0031039-Exome1], is a database with exome sequencing data for 1,326 European-American and 1,067 African-American selected for heart, lung and blood disorders. In this database there were reported 198 novel and rare non-synonymous, nonsense or splice-site variants in these 2,393 individuals, which is statistically lower than in our series (p = 1.79×10^−4^; OR = 1.79; 95%CI = 1.31--2.43). These results most likely reflect the increased recurrence risk among densely affected LOAD families. It is possible therefore that some of these new variants could be pathogenic or disease modifiers.

10.1371/journal.pone.0031039.t003

###### Number of rare non-synonymous and splice-site variants found in the 439 sequenced samples.
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           Previously reported   New[\*\*](#nt104){ref-type="table-fn"}                                                              
  ------- --------------------- ---------------------------------------- --- ------ --- ------ --- ------ --- ------ --- ------ ---- -------
  APP               0                              0                      0    0     1    1     1    1     2    2     2    3     6      7
  PSEN1             2                              7                      0    0     0    0     0    0     1    1     0    0     3      8
  PSEN2             0                              0                      3    13    0    0     0    0     0    0     0    0     3     13
  MAPT              0                              0                      1    1     0    0     1    1     1    1     4    12    7     15
  GRN               3                              3                      1    1     4    4     1    2     3    4     2    3     14    17
  total             5                              10                     5    15    5    5     3    4     7    8     8    18    33    60
                                                  2.3%                        3.4%       1.1%       0.9%       1.8%       4.1%        13.7%

\*Based on our segregation analyses.

\*\*Not present in the AD&FTD mutation database or in dbSNP.

Only the rare (MAF\<0.05) non-synonymous, splice-site and nonsense sequence variants are shown.

Pathogenic or likely pathogenic mutations {#s2a}
-----------------------------------------

We identified eight sequence variants, one each in *APP* and *MAPT*, two in *PSEN1*, and four in *GRN*, in a total of 14 families (3.2% of the total families) that are known to cause disease or appear to be highly penetrant rare pathogenic alleles, based on segregation data, bioinformatics and sequence data in additional controls. Three of these variants are novel and five were previously reported ([Table 4](#pone-0031039-t004){ref-type="table"}, [5](#pone-0031039-t005){ref-type="table"} and [Table S2](#pone.0031039.s004){ref-type="supplementary-material"}). The sequence variants showing perfect segregation were the previously reported pathogenic G206A mutation in *PSEN1* [@pone.0031039-Rogaeva1], [@pone.0031039-Athan1], the previously reported pathogenic variant *GRN* R110X [@pone.0031039-VanDeerlin1], [@pone.0031039-Yu1] and *GRN* G515A. In each family, all of the genotyped affected individuals carried the sequence variants, but none of the unaffected individuals were carriers. *PSEN1* G206A and *GRN* R110X were not found in 1,806 AD cases and 1,346 unrelated controls. *GRN* G515A was found in an additional AD case of European-descent (from the 1,806 screened) but not in the 1,346 unrelated controls.

10.1371/journal.pone.0031039.t004

###### List of the pathogenic and likely pathogenic non-synonymous, splice site and nonsense sequence variants identified.
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  Gene                                  Change      \# of fam                 Status                 Polyphen2prediction   Affected    Unaffected              
  --------------------------------- -------------- ----------- ------------------------------------ --------------------- ----------- ------------ ----------- -------------
  Pathogenic or likely pathogenic                                                                                                                              
  APP                                   N660Y           1                     Novel                   probably damaging        3           0            1            1
                                                                                                                            61.6±3         \-          62           69
  PSEN1                                  A79V           4         Previously reported Pathogenic      probably damaging       10           1            3           13
                                                                                                                           68.9±8.5        77        60±4.3     70.62±12.95
                                        G206A           3         Previously reported Pathogenic      probably damaging        6           0            0            1
                                                                                                                           60.8±6.7        \-          \-           40
  MAPT                                  G201S           1                     Novel                   probably damaging        2           0            2            2
                                                                                                                             74±0          \-        61±5.7       49±4.2
  GRN                                   R110X           1         Previously reported Pathogenic      probably damaging        3           0           0-            5
                                                                                                                           66.3±2.1        \-          \-        72.2±5.26
                                     c.1414-1G\>T       2                     Novel                   probably damaging        8           1            0            1
                                                                                                                           65.8±11.7       74          \-           70
                                        R493X           1         Previously reported Pathogenic      probably damaging        1           3            4            3
                                                                                                                              70       78.3±1.15    56.3±4.04   56.3±11.06
                                        G515A           1       Previously reported Not pathogenic    probably damaging        3           0            0            1
                                                                                                                            80±7.5         \-          \-           66

List of the non-synonymous, splice and nonsense variants identified in the 439 sequenced samples. The identified variants were genotyped in all the available family samples. The number of affected carriers, non-carriers and the un-affected carriers, non-carriers, as well as the mean age at onset and the standard deviation for the affected and the age at last assessment for the unaffected individuals are shown.

The variants were classified as pathogenic, or likely pathogenic based on our segregation analyses, bioinformatic analyses, sequencing and genotyping data in additional cases and controls ([table 5](#pone-0031039-t005){ref-type="table"}) and previous reports.

10.1371/journal.pone.0031039.t005

###### Allele frequency of all variants in the initial dataset and in additional case-control series.
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                                          familial cases   AD cases   Controls+unselected                                        
  ----------------------- -------------- ---------------- ---------- --------------------- ---------- ------- ------------------ -------
  APP                         N660Y          European       1/439            0.228          0/1,806    0.000   0/(1,346+12,481)   0.000
  MAPT                        G201S          European       1/439            0.228          1/1,806    0.055       0/1,346        0.000
  GRN                      c.1414-1G\>T     Hispanics       2/439            0.456          0/1,806    0.000       0/1,346        0.000
                              G515A         Hispanics       1/439            0.228          1/1,806    0.055       0/1,346        0.000
  Likely non-pathogenic                                                                                                          
  APP                         G322A         Hispanics       1/439            0.228          0/1,806    0.000       0/1,346        0.000
                              E599K          European       2/439            0.456          2/1,806    0.111       2/1,346        0.148
                              A673T          European       1/439            0.228          0/1,806    0.000       0/1,346        0.000
  PSEN2                        R62H           Mixed         6/439            1.367          18/1,806   0.997       13/1,346       0.965
                               R71W          European       6/439            1.367          26/1,806   1.439       3/1,346        0.222
                              M174V          European       1/439            0.228          3/1,806    0.166       0/1,346        0.000
  MAPT                         R5H           European       1/439            0.228          1/1,806    0.055       0/1,346        0.000
                              R168C          European       1/439            0.228          3/1,806    0.166       0/1,346        0.000
                              A152T          European       5/439            1.140          17/1,806   0.941       6/1,346        0.445
                              V224G          European       2/439            0.456          10/1806    0.553       12/1,346       0.891
                              A239T          European       4/439            0.911          4/1,806    0.221       4/1,346        0.297
  GRN                          P85A          European       2/439            0.456          0/1,806    0.000       0/1,346        0.000
                              V141I          European       1/439            0.228          0/1,806    0.000       0/1,346        0.000
                              T268M          European       1/439            0.228          1/1,806    0.055       0/1,346        0.000
                              A324T          European       1/439            0.228          5/1,806    0.277       2/1,346        0.148
                              D376N          European       1/439            0.228          0/1,806    0.000       0/1,346        0.000
                              R433Q          European       1/439            0.228          0/1,806    0.000       0/1,346        0.000
  Unknown                                                                                                                        
  APP                         G191E          European       1/439            0.228          0/1,806    0.000   0/(1,346+12,481)   0.000
                              V340M         Hispanics       1/439            0.228          0/1,806    0.000   0/(1,346+12,481)   0.000
  PSEN1                        P7L           European       1/439            0.228          0/1,806    0.000       0/1,346        0.000
  MAPT                        S427F         Hispanics       1/439            0.228          0/1,806    0.000       0/1,346        0.000
  GRN                         D135V         Hispanics       1/439            0.228          0/1,806    0.000       0/1,346        0.000
                              M207T          European       1/439            0.228          0/1,806    0.000       0/1,346        0.000
                              V514M          European       1/439            0.228          0/1,806    0.000       0/1,346        0.000
                              V519M         Hispanics       2/439            0.456          2/1,806    0.110       7/1,346        0.520

The novel variants that were classified as likely pathogenic or unknown were genotyped in an additional 1,806 unrelated AD cases and 1,346 controls. Among the 1,346 controls 113 are of Hispanic origin. The GSK dataset (n = 12,481, were also used to analyze the presence of some variants in *APP*, *PSEN1* and *PSEN2*).

The *PSEN1* A79V mutation was found in four of the 439 sequenced samples ([Table 3](#pone-0031039-t003){ref-type="table"} and [4](#pone-0031039-t004){ref-type="table"}), including the most densely affected family with 28 affected individuals ([Table 1](#pone-0031039-t001){ref-type="table"}). The mutation in this family was reported previously by sequencing samples with extreme cerebrospinal fluid Aβ levels [@pone.0031039-Kauwe1]. The sequenced individual from this family had autopsy confirmed AD and an AAO of 76 years, which was similar to the mean AAO in the entire family. Although A79V is a known pathogenic mutation, seen in families with early onset AD [@pone.0031039-Cruts1], [@pone.0031039-Rogaeva1], the mutation did not show perfect segregation with disease in this family ([Figure 1A](#pone-0031039-g001){ref-type="fig"}). One of the four genotyped affected individuals (AAO 77 years) did not carry the mutation, possibly representing a phenocopy. In addition, three unaffected individuals carried the mutation but their mean age at last assessment was more than ten years below the mean onset of disease in the family. These individuals are likely presymptomatic. *PSEN1* A79V was found also in a sporadic AD case (from the 1,806 screened), but not in the 1,346 unrelated controls.

![Pedigrees for some of the sequenced families illustrating the presence of phenocopies and low penetrance mutations or the presence of presymptomatic cases.\
A) Pedigree for a family with the *PSEN1 A79V* mutation. B) Pedigree for a family with the *GRN R493X* mutation. AO indicates the subject or family report of age of onset of symptoms. AE = the age of last evaluation. MCI: Mild cognitive impairment or questionable dementia by family report.+symbol indicates that the subject is positive for the indicated mutation.−symbol indicates that the subject is negative for the indicated mutation. A number inside of a diamond indicates the number of subjects with the same status. Fully shaded circles or squares indicate confirmed AD by autopsy. Three/fourths shaded symbol indicates probable AD diagnosed using NINCDS-ADRDA criteria. One/fourth shaded symbol indicates that the family reports this individual has AD.](pone.0031039.g001){#pone-0031039-g001}

For the novel variants *APP* N660Y (exon 16) and *MAPT* G201S (exon 9), some of the carriers were asymptomatic at the time of the last assessment ([Table 4](#pone-0031039-t004){ref-type="table"}), but in all cases, the age at last assessment of the unaffected carriers is lower than the oldest age at onset for the affected carriers. Both *APP* N660Y, and *MAPT* G201S are predicted to be damaging by Polyphen2 [@pone.0031039-Adzhubei1]. The *APP* N660Y variant was not found in 1,806 AD cases, 1,346 unrelated controls, nor in the 12,481 subjects not enriched for AD (GSK study), nor in the Exome Variant Server. The *MAPT* G201S variant was found in an additional case from the NIA-LOAD study (from the 847 screened). The *MAPT* G201S variant was present in the affected sibling but not in an unaffected family member. This variant was not found in 1,346 unrelated elderly non-demented controls ([Table 5](#pone-0031039-t005){ref-type="table"}), nor in the Exome Variant Server.

An additional known pathogenic mutation, R493X, and a novel potentially pathogenic variant, c.1414-1G\>T, were identified in *GRN*. However as with the *PSEN1* A79V mutation, these *GRN* variants do not show perfect segregation ([Table 4](#pone-0031039-t004){ref-type="table"}, [Figure 1B](#pone-0031039-g001){ref-type="fig"}). The R493X mutation was present in a single demented individual (AAO = 70), but was absent in another three demented individuals (AAO = 78.3±1.15), suggesting that these non-carriers are phenocopies. Four young unaffected individuals are also mutation carriers. The R493X has been found in more than 12 FTD kindreds (AD&FTD mutation database) and functional data has shown that the mutation results in a premature termination codon causing nonsense-mediated mRNA decay [@pone.0031039-VanDeerlin1], [@pone.0031039-Huey1]. In the families with the *GRN* c.1414-1G\>T variant we also found a single affected individual who did not carry the sequence variant. The age at onset of this individual is higher than the mean onset for the affected individuals carrying the sequence variant, suggesting that this individual may be a phenocopy. The *GRN* splice-site variant c.1414-1G\>T affects the last nucleotide of intron 10 within a core splice-site. This variant was found in two Hispanic families, one of which had 20 affected individuals. This variant is predicted to alter an acceptor splice-site (NetGene2 Prediction score for the wild type variant 1.00 vs. 0.00 for the mutant) causing exon skipping. A recent screen for *GRN* pathogenic mutations identified a similar variant (c.1414-2A\>G) affecting the same core splice-site. *Ex vivo* splicing assays confirmed that the mutation c.1414-2A\>G affects splicing of the exon [@pone.0031039-Yu1]. Neither the *GRN* R493X nor the c.1414-1G\>T variant were found in the controls or in the sporadic AD cases ([Table 5](#pone-0031039-t005){ref-type="table"}), nor the Exome Variant Server. None of the sequenced individuals with pathogenic or likely pathogenic mutations in *GRN* or *MAPT* had neuropathologic confirmation of diagnosis. These individuals most likely have frontotemporal dementia that has a clinical presentation indistinguishable from AD.

The literature [@pone.0031039-Yu1], segregation data, the absence of variant carriers among non-demented controls, and our bioinformatic analyses strongly suggest that *APP* N660Y, *MAPT* G201S and *GRN* c.1414-1G\>T are rare pathogenic alleles exhibiting high disease penetrance.

Non-pathogenic or likely non-pathogenic variants {#s2b}
------------------------------------------------

We identified a total of thirteen (eight novel) sequence variants (23 families) which clearly did not segregate with disease and/or were found in controls suggesting that these variants are not causative mutations ([Table 5](#pone-0031039-t005){ref-type="table"} and [Table S2](#pone.0031039.s004){ref-type="supplementary-material"}), but our analyses suggest that some of them may be disease modifiers. Some of these variants (*PSEN2* R71W and M174V, and *MAPT* R5H) were previously classified as pathogenic in the AD&FTD mutation database; however our results do not support this designation. These variants occurred in multiple families but did not segregate with disease status in any family ([Table S2](#pone.0031039.s004){ref-type="supplementary-material"}) and were observed multiple times in the unselected samples and the elderly non-demented controls samples ([Table 5](#pone-0031039-t005){ref-type="table"}).

The majority of the genetic variants identified in these genes, so far, have been classified as pathogenic or non-pathogenic, but rare variants in these genes could also be risk factors for disease. Carriers of the R62H and R71W *PSEN2* variants have a significantly earlier age at onset than affected non-carriers even after correcting for *APOE* genotype (R71W: 70.2 vs 76.7, p = 0.0005; R62H: 71 vs 75 years, p = 0.0019; [Table S3](#pone.0031039.s005){ref-type="supplementary-material"}), suggesting that these variants could be disease modifiers.

The novel variant *APP* G322A was present in four affected individuals but absent in 7 additional affected members from the same family and therefore does not segregate with disease. This variant was not found in 12,481 samples unselected for AD (P = 1.0×10^−7^). The bioinformatic analyses predict it as probably damaging. These data suggest that the *APP* G322A variant may be a risk factor for AD, but more studies will be necessary to confirm this hypothesis.

The frequency of these variants is, in most cases, higher in AD cases than in controls. As these variants have very low frequency, the power to identify significant differences in cases vs. controls is very limited. However, if we combine all of the novel variants classified as non-pathogenic ([Table 5](#pone-0031039-t005){ref-type="table"}), the frequency of these variants in AD cases is significantly higher than in controls (5.66% in AD cases vs 2.89% in controls; p = 3.11×10^−4^; OR = 1.86; 95%CI = 1.30--2.65), suggesting that these variants may increase risk for AD, although they are not causative. See Supporting [Results S1](#pone.0031039.s002){ref-type="supplementary-material"} for full results about the likely non-pathogenic variants unknown pathogenicity.

Variants with unknown pathogenicity {#s2c}
-----------------------------------

For eight novel variants (*APP* G191E and V340M; *PSEN1* P7L; *GRN* D135V, M207T, V514M, V519M; and *MAPT* S427F), segregation within families was inconclusive, in part due to the small number of family members sampled. The *APP* and *PSEN1* variants were absent from the 12,481 unselected samples, and the *GRN* D135V and V514M and *MAPT* mutation were not found in 1,346 non-demented elderly controls ([Table 5](#pone-0031039-t005){ref-type="table"}). Bioinformatics analyses predict that the *APP*, *MAPT*, *and GRN* V519M variants are probably damaging ([Table S2](#pone.0031039.s004){ref-type="supplementary-material"}). The total number of variants in AD cases is significantly higher than in controls (2.23% in AD cases vs 0.52% in controls; p = 9.46×10^−12^; OR = 4.38; 95%CI = 1.65--11.57) strongly suggesting that some of these novel variants may cause or increase risk for AD.

Impact of *APOE* genotype in these families {#s2d}
-------------------------------------------

*APOE* is the strongest known genetic risk factor for sporadic and familial LOAD. Therefore we analyzed the effect of *APOE* in these families. We initially compared the *APOE4* allele frequency in the sequenced samples comparing carriers for rare sequence variants against the non-carriers. There was no significant difference between these two groups (71.15% vs 72.29% p = 0.86). However we found that the *APOE4* allele frequency in these families is significantly higher compared to sporadic AD cases (72.13% vs. 60%, p = 2.18×10^−6^, OR = 1.71, 95%CI: 1.36--2.17) and controls (72.13% vs. 26%, p = 5.28×10^−85^; OR = 7.37, 95%CI: 5.86--9.27)(APOE4 frequencies obtained from Alzgene). These results confirm that *APOE* is a strong genetic risk factor in these families, and suggest that the *APOE4* genotype could be sufficient to cause disease in some of these families, as suggested in a recent report [@pone.0031039-Genin1]. However, we found likely causative variants in individuals with every *APOE* genotype and no difference in the *APOE4* frequency among the samples with and without rare sequence variants. As reported previously, we found that *APOE4* is associated with a dose dependent decrease in the AAO ([Table S3](#pone.0031039.s005){ref-type="supplementary-material"} and [Figure S1](#pone.0031039.s008){ref-type="supplementary-material"}). *APOE4* carriers with a rare sequence variant in the screened genes have a lower AAO than *APOE4* carriers without a rare sequence variant in these genes (67.3 y vs. 69.8 y; p = 0.025), suggesting that these sequence variants modify AAO of AD independently of *APOE* genotype.

Comparison of the individuals and families with and without sequence variants {#s2e}
-----------------------------------------------------------------------------

The age at onset of individuals with rare non-synonymous variants in these genes was significantly lower than that for sequenced individuals with normal gene sequence (67.8 years vs 70.5 years p = 0.004), but there was no difference in the mean age at onset in families with rare non-synonymous variants compared to those without sequenced variants ([Table S4](#pone.0031039.s006){ref-type="supplementary-material"}). The major feature differentiating the families with novel rare variants from those with normal gene sequence was the reported number of affected individuals per family. We found that the families with rare sequence variants had significantly more affected individuals than families without sequence variants (average = 6.88 vs 5.62; p = 0.0008; [Figures S2](#pone.0031039.s009){ref-type="supplementary-material"}, [S3](#pone.0031039.s010){ref-type="supplementary-material"}, [S4](#pone.0031039.s011){ref-type="supplementary-material"}, [Table S4](#pone.0031039.s006){ref-type="supplementary-material"}).

Discussion {#s3}
==========

Pathogenic mutations in *APP*, *PSEN1*, *PSEN2*, *MAPT* and *GRN* have previously been linked to familial early onset forms of dementia. A recent report looking at common variants in *APP*, *PSEN1*, *PSEN2* and *MAPT* in a large case-control sample consisting of 3,940 cases and 13,373 controls, found that common variants in these genes are unlikely to make strong contributions to susceptibility for LOAD [@pone.0031039-Gerrish1]. However, the impact of rare variants in these genes in late onset clinically diagnosed AD remains unclear. This is the first study to systematically screen for rare variants and pathogenic mutations in *APP*, *PSEN1*, *PSEN2*, *MAPT* and *GRN* in a large clinical series of well-characterized families densely affected by LOAD.

We found seven families carrying two known causative mutations in *PSEN1* (A79V and G206A [@pone.0031039-Cruts1]--[@pone.0031039-Athan1]), and three families carrying two clearly causative mutations in *GRN* (R110X, R493X [@pone.0031039-Huey1], [@pone.0031039-Rademakers1], [@pone.0031039-Yu1], [@pone.0031039-Gass1]--[@pone.0031039-Spina1]. In some families these causative mutations (*PSEN1*-A79V, and *GRN*-R493X, [Figure 1](#pone-0031039-g001){ref-type="fig"}) did not completely segregate with disease, illustrating how phenocopies, potential presymptomatic individuals and reduced penetrance may complicate the interpretation of novel sequence variants in familial and sporadic LOAD. While we can identify the phenocopies in families with known mutations, as in the case of *PSEN1* A79V and *GRN* R110X ([Fig. 1](#pone-0031039-g001){ref-type="fig"}), it is more challenging in families with novel variants, because phenocopies might be interpreted as a failure of the variant to segregate with disease. Putative pathogenic variants in genes that cause late onset rather than early onset dementia could have a less severe effect on protein function due to other genetic or environmental modifiers that are not present when these same variants result in early onset disease. This would lead to the occurrence of reduced penetrance. Indeed, several cases of reduced penetrance have been reported in families with *PSEN1* and *GRN* mutations [@pone.0031039-Gass1], [@pone.0031039-Rossor1]--[@pone.0031039-Foster1]. Despite these problems in our segregation data, the absence of these variants in a large non-demented control series and the bioinformatics analyses suggest that the novel variants *APP* N660Y, *GRN* c.1414-1G\>T and *MAPT* G201S are likely to be causative mutations or highly penetrant rare disease alleles.

In total 14 (3.2%) of the 439 sequenced samples from densely affected families carried a causative or likely-causative mutation. Although this percentage is low, the overall number of LOAD cases carrying mutations in these genes is likely to be higher than the number of early onset cases, because LOAD is much more frequent. Approximately 10--20% of all patients with LOAD have a family history of dementia. Of those, approximately 10% have a history of four or more affected family members. Based on our analysis, we estimate 3.2% of these densely affected families would have a causative mutation. Thus, 0.029--0.057% of all patients with LOAD may carry a pathogenic mutation in these genes, representing a minimum of 1,917--3,833 cases in the United States.

It is likely that we have underestimated the actual number of cases with causative mutations. First, the recurrence risk in family members peaks with an age-at-onset of 85 years in the proband [@pone.0031039-Silverman1], [@pone.0031039-Silverman2]. Several families with more than 10 affected individuals have no mutations in the genes studied here. Thus it is very likely that there are novel AD causative genes yet to be discovered. Second, some of the variants with unknown pathogenicity reported in this study, such as, *APP G220E* and V340M, *and MAPT* S427F, could be pathogenic, or risk factors. The scarcity of available DNA samples from other family members with LOAD made it difficult to determine whether or not these novel variants segregate with disease. However, we did not find these variants in additional controls and the bioinformatic analyses suggest that these variants may be pathogenic. To confirm this hypothesis more genetic and functional analyses will be necessary. Lastly, some of the variants we found in this study (*APP* A79V, *MAPT* G201V and *GRN* G515A) were also found in sporadic cases, but not in controls. These results indicate that novel mutations remain to be discovered and that mutations in these genes are also present in LOAD cases with no clear family history. Together these results suggest that any individual with a family history of dementia affecting a large number of relatives and with an onset in the mid-60s should be considered for mutation screening not only of the AD genes (*APP*, *PSEN1* and 2), but also *MAPT* and *GRN*. Our study also indicates that mutations in these genes can be present in 1 to 3% of the sporadic cases. These cases may be classified as sporadic because the family size is small, because of the lack of medical records for other family members or because the variant has low penetrance.

Another important finding is the observation of clinically diagnosed AD families carrying previously reported and likely novel pathogenic mutations in *GRN* and *MAPT*. Mutations in these genes are typically associated with frontotemporal lobar degeneration [@pone.0031039-VanDeerlin1], [@pone.0031039-Huey1], but have been previously reported in clinically diagnosed AD cases [@pone.0031039-Cortini1]--[@pone.0031039-Reed1]. Our results show that mutations in *GRN* and *MAPT* in a clinical series of LOAD families are as common as mutations in the AD genes (*APP*, *PSEN1* and *2*). Six families (1.37%) with pathogenic or likely pathogenic mutations in *GRN* and *MAPT* were found vs. eight families (1.82%) with mutations in *APP* and *PSEN1*. None of the individuals with *MAPT* or *GRN* mutations had autopsy confirmation of the clinical diagnosis. It is most likely that these individuals have been misdiagnosed and that neuropathological diagnosis for these individuals will be FTD and not AD.

Our study indicates that families carrying mutations in *GRN* or *MAPT* can present with disease that is clinically indistinguishable from probable AD even in specialist memory disorder clinics, which is analogous to the observations that "AD mutations" can present with frontotemporal lobar degeneration [@pone.0031039-Mendez1]--[@pone.0031039-Marcon1]. Identification of families and individuals carrying mutations in genes associated with frontotemporal lobar degeneration will be important for clinical management of these patients, particularly as therapies are developed that target the specific pathophysiologic processes of these disorders.

Some of the rare variants discovered in this study appear to increase the risk for AD or modify the age at onset. We found a very significant association of *PSEN2* R62H and R71W with age at onset. It is very likely that some of the variants classified as non-pathogenic also increase risk for AD: When the individuals with variants classified as pathogenic are removed (n = 14), and the frequency of rare non-synonymous variants is compared with 1,000 genome project data (p = 1.93×10^−3^; OR = 2.18, 95%CI: 1.31--3.62), the GSK dataset (p = 5.99×10^−3^; OR = 1.89, 95%CI: 1.19--3.00) or the Exome Variant Server (p = 0.010; OR = 1.48; 95%CI = 1.06--2.06), there is still a significant excess of rare variants in these genes in the LOAD cases. In the three datasets (GSK 1,000 genome project, and Exome Variant Server) a large proportion of samples are of non-European origin, therefore some of the variants found in these datasets may represent population specific alleles, decreasing the power of our analyses. If we focus on the specific variants found in this study and compare their frequency in elderly non-demented individuals, we found that these variants may have a big impact on AD risk. The eight variants classified as "unknown pathogenicity" have a combined OR = 4.38 (95%CI = 1.65--11.57), and the variants classified as "non-pathogenic" have a combined OR = 1.86 (95%CI = 1.30--2.65). The common variants identified in the last GWAS for AD had ORs ranging from 1.26 to 1.11, with a combined OR of 2.23. Therefore an individual carrying a single rare variant in one of these genes has a higher likelihood of developing AD than individuals varying all of the risk alleles for the novel genes found in the recent GWAS studies. This is the first large study looking at the effect of rare variants in candidate genes in AD. Additional large studies are needed to replicate these findings.

This work provides some general guidelines to identify individuals and families that should be prioritized for genetic counseling and mutation screening. Although we did not find clear phenotypic differences between the families carrying missense, splice-site or nonsense variants compared with the families without novel variants, the number of reported affected individuals and the presence of at least one affected individual with an early age at onset were strong indicators of the presence of a pathogenic variant. Given the significant overlap in clinical presentation, individuals with a strong family history of AD should also be screened for mutations in *MAPT* and *GRN*, genes typically associated with frontotemporal lobar degeneration, when no autopsy is available. In families with a history of four or more affected individuals and with an onset in the mid-60s, genetic testing may be considered for *PSEN1-2*, *APP*, *GRN* and *MAPT*. Families with multiplex late onset dementia should be referred to genetic counsellors.

Rare coding variants in *APP*, *PSEN1 and PSEN2*, increase risk for or cause late onset AD. Dividing AD into late onset and early onset is probably not useful from a mechanistic point of view because mutations in *APP*, *PSEN1 and PSEN2* can be found in early onset and late onset AD. Similarly, *APOE4* increases risk for AD in both early and late onset AD. Clearly factors other than the mutation can impact the age at onset and penetrance of at least some variants causing AD. *MAPT* and *GRN* mutations can be found in clinical series of AD most likely due to misdiagnosis. Finding a mutation in these genes would change the clinical diagnosis in a demented individual. This will be particularly important when mechanism-based therapies become available because this would change the treatment of these individuals. Lastly, familial aggregation is more important than age at onset in determining the likelihood of an individual carrying a disease-causing variant.

Materials and Methods {#s4}
=====================

Patients {#s4a}
--------

The NIA-LOAD Family Study recruited 992 multiplex LOAD families, with at least two living affected individuals, from throughout the United States. A description of these samples has been reported previously [@pone.0031039-Wijsman1]. We selected for sequencing all families (439) that met the following criteria: at least 4 family members reported with a history of dementia consistent with LOAD, and either at least two affected family members reporting an age of onset of 65 years or older or an average age of onset in the family of 60 years or older ([Table 1](#pone-0031039-t001){ref-type="table"}). The youngest affected family member with the most definitive diagnosis was selected for sequencing. In some families the age at onset for the sequenced sample was lower than 60 years, but the mean age at onset for the entire family was equal to or greater than 60 years ([Table 2](#pone-0031039-t002){ref-type="table"}). We chose individuals with autopsy confirmed disease (26.9%) over those with probable (71.4%) or possible (1.5%) disease (NINCDS-ADRDA) [@pone.0031039-McKhann1]. Written consent was obtained from all participants, and the study was approved by the local IRB committees.

DNA sequencing and genotyping {#s4b}
-----------------------------

We used the next-generation, pooled-DNA method described by Druley et al. [@pone.0031039-Druley1], and Vallania et al. [@pone.0031039-Vallania1] to identify sequence variants in *APP*, *PSEN1*, *PSEN2*, *MAPT* and *GRN*. A more detailed description of this method is provided in the Supporting [Materials and Methods S1](#pone.0031039.s001){ref-type="supplementary-material"} and [Table S1](#pone.0031039.s003){ref-type="supplementary-material"}. All rare (minor allele frequency\<5%) missense, nonsense, and splice-site sequence variants identified in the pooled DNA experiment were confirmed and the specific sample carrying the variant was identified by direct genotyping using standard procedures for Sequenom, Taqman or Kaspar. We genotyped the confirmed variants in all available family members to determine whether the sequence variant segregated with disease. Common variants and synonymous variants were not followed up.

Bioinformatics {#s4c}
--------------

PolyPhen2 [@pone.0031039-Adzhubei1] and Net2Gene [@pone.0031039-Brunak1] were used to evaluate the effect of non-synonymous and splice-site variants on protein function and structure. The AD&FTD mutation database (<http://www.molgen.ua.ac.be/ADMutations/>) was used to identify sequence variants found in previous studies of early onset familial dementia and to determine whether or not they were considered to be disease-causative variants. The sequencing data from the 1,000 genome project and the GlaxoSmithKline study (GSK study; see below and supporting [Materials and Methods S1](#pone.0031039.s001){ref-type="supplementary-material"} and [Table S5](#pone.0031039.s007){ref-type="supplementary-material"}) were used to estimate the frequency of novel and rare (minor allele frequency less than 5%) missense, nonsense and splice site variants in samples unselected for studies of AD. For *APP*, *PSEN1* and *PSEN2* we had access to sequence data from the GSK study for the exons of these genes including variant counts and allele frequencies for 12,481 individuals from 10 disease collections and 2 population-based studies all unselected for AD. Average age of exam for this sample was 51.7 years. This dataset included 10,967 Caucasians, 594 African-Americans, 566 South Asians, 84 Ashkenazi Jews, 29 Hispanics and 241 individuals of mixed ethnicity (see supporting [Materials and Methods S1](#pone.0031039.s001){ref-type="supplementary-material"}).

Genotyping additional cases and controls {#s4d}
----------------------------------------

All variants classified as "likely pathogenic" or with an "unknown pathogenicity", and some "non-pathogenic" variants were genotyped in 961 sporadic AD cases, 1,346 unrelated elderly non-demented controls [@pone.0031039-Hollingworth1], [@pone.0031039-Naj1] and a single case from each of the remaining NIA-LOAD families (n = 847 with \</ = 3 affected individuals) [@pone.0031039-Wijsman1].
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